Frontotemporal Dementia: A Randomised, Controlled Trial with TrazodoneLebert F.a · Stekke W.b · Hasenbroekx C.c · Pasquier F.a
aMemory Clinic, Lille University Hospital, Lille, France; bPharmacia Laboratory, Diegem, cDepartment of Neurology, Heilig Hart Ziekenhuis, Roeselare, Belgium
Behavioural troubles due to frontotemporal dementia (FTD) are difficult to treat. The serotonergic system is associated with frontal lobes, the degeneration of which contributes to FTD. Trazodone increases the extracellular 5-HT levels in the frontal cortex. In a randomised, double-blind, placebo-controlled cross-over study, we investigated the effect of trazodone. There was a significant decrease in the Neuropsychiatry Inventory (NPI) total score with trazodone (p = 0.028) in the 26 evaluable patients. A decrease of more than 50% in the NPI score was observed in 10 patients with trazodone. This improvement was mainly based on the improvement of 4 items of the scale (irritability, agitation, depressive symptoms and eating disorders). The Mini-Mental State Examination was not modified and trazodone was well tolerated. Results of this first placebo-controlled trial suggest that trazodone is an effective treatment for the behavioural symptoms of FTD.
© 2004 S. Karger AG, Basel
Dr. Florence Lebert
Centre de la Mémoire, Hôpital Roger Salengro
Centre Hospitalier Universitaire
FR–59037 Lille (France)
Tel. +33 3 20 44 60 21, Fax +33 3 28 43 47 46, E-Mail firstname.lastname@example.org
Number of Print Pages : 5
Number of Figures : 2, Number of Tables : 2, Number of References : 14
Dementia and Geriatric Cognitive Disorders
Vol. 17, No. 4, Year 2004 (Cover Date: Released June 2004)
Journal Editor: V. Chan-Palay, New York, N.Y.
ISSN: 1420–8008 (print), 1421–9824 (Online)
For additional information: http://www.karger.com/journals/dem